Navigation Links
For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
Date:5/18/2009

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to treat the disease. In 2008, TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira accounted for 80 percent of rheumatoid arthritis drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative biologics such as Roche/Chugai's Actemra/RoActemra will take market share away from the TNF-alpha inhibitors as interviewed rheumatologists indicate they switch to one of these agents for patients who respond inadequately to two TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred agent for TNF-refractory patients and is forecasted to achieve sales of nearly $2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and is expected to take significant market share away from Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the indication following its recent approval for rheumatoid arthritis by the Food and Drug Administration. Additionally, an emerging agent from Pfizer is expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal patient share from the
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes
2. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
3. Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
4. The future of personalized cancer treatment: An entirely new direction for RNAi delivery
5. An Aid to Tailoring Prostate Cancer Treatment
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
8. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
9. Can New Surgery Revolutionize Diabetes Treatment?
10. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
11. New Cancer Treatment Achieves First Mesothelioma Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated ... of beach wedding dresses. “If you are looking for ... as soon as possible. Here you can enjoy 70% ... says. , Holding a big marriage ceremony is the ... beautiful beach wedding dress is uppermost priority. Ophelia, one ...
(Date:11/23/2014)... CA (PRWEB) November 23, 2014 ... American Medical Aesthetics & Wellness was recently featured ... Milgrom, Ph.D. is president and CEO of American Medical ... Dr. Asher Milgrom received a full scholarship to attend ... the Medical School at the University of Chicago, where ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... Development, and Health at Harvard School of Public Health, has ... found that the disease costs a person $3.2 million over ... the new book Understanding Autism: From Basic Neuroscience to Treatment ... Autism,” Ganz says that autism costs $35 billion per year ...
... open a second cancer hospital, this time in the southern ... up in Karachi by January next year, the Daily Times ... had set up the Shaukat Khanum Memorial Cancer Hospital and ... state-of-the-art cancer centre was Khan's tribute to his mother Shaukat ...
... of the Irish Medical Organization (IMO) has expressed his interest ... . Previously, Nora Owen, the party’s former Justice Minister held ... nomination in the Dublin North constituency and is positive about ... held on the 2nd of May. ,‘The people ...
... flu in ducks on Indonesia's resort island of Bali, health ... of bird flu// . The birds had been smuggled to ... Putra, senior government veterinarian. ,More than 24 bird ... most populous nation. In response to the above situation, import ...
... Researchers from the Simon Bolivar University in Caracas found ... the beans reduced its flatulence capacity// and increased the ... of nutrition especially in the developing countries. ... method of creating flatulence-free beans but not compromising on ...
... University suggests that men are more aware of potential rivals ... The researchers felt that men// become more jealous and wary ... their most fertile. ,The Evolution and Human Behaviour ... with ovulating partners were vary wary of the dominant looking ...
Cached Medicine News:Health News:The Price Of Autism 2Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2
(Date:11/22/2014)... , Nov. 22, 2014  Sprout Pharmaceuticals today announced ... demonstrate that women treated with flibanserin up to 200 mg ... data were presented at the 20 th Annual Fall ... North America in Miami . ... response to the Complete Response Letter and the Formal Dispute ...
(Date:11/22/2014)... , Nov. 22, 2014  New data demonstrates ... the most common form of female sexual dysfunction, Hypoactive ... function or driving performance in premenopausal women when taken ... Medicine Society of North America,s ... Miami . SMSNA accepted this ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... 16 , - Promising Efficacy ... Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) ... II studies evaluating,the efficacy, safety and tolerability of QVA149 at ... QVA149 is a novel once-daily,dry powder fixed dose bronchodilator combination ...
... , , ... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from ... 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ...
Cached Medicine Technology:QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 2QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 3QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6
... Millbrook Practice Manager® is now known ... (PM). Centricity Physician Office - PM is ... and structure, providing an easily adaptable solution ... physician offices of every specialty and ...
... practice management systems have brought cutting-edge software ... in the world. Today, Intuition PM delivers ... a friendly, intuitive manner. Automate patient registration ... in-office patient processing through wireless hand-held PC's, ...
... Electronic Medical Records module is designed ... costs and increase revenues. It creates ... minimal effort while it streamlines workflow, ... related to patient care outcomes. NextGen ...
... Intuition EMR family of products offers ... range of specialties. Intuition EMR enables ... full electronic record at the point ... spend less time on documentation and ...
Medicine Products: